Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Randomized, Double Blind, Placebo Controlled Study to Determine the Efficacy and Safety of CMB305 in Unresectable Locally Advanced or Metastatic NY ESO 1+ Synovial Sarcoma Subjects Following First Line Systemic Anti Cancer Therapy (Synovate Study)

Trial Profile

A Phase 3, Randomized, Double Blind, Placebo Controlled Study to Determine the Efficacy and Safety of CMB305 in Unresectable Locally Advanced or Metastatic NY ESO 1+ Synovial Sarcoma Subjects Following First Line Systemic Anti Cancer Therapy (Synovate Study)

Discontinued
Phase of Trial: Phase III

Latest Information Update: 23 Nov 2018

At a glance

  • Drugs CMB 305 (Primary)
  • Indications Synovial sarcoma
  • Focus Registrational; Therapeutic Use
  • Acronyms Synovate
  • Sponsors Immune Design
  • Most Recent Events

    • 11 Oct 2018 According to an Immune Design media release, based on the results of phase 2 study of Synovial sarcoma, the company has decided to discontinue this phase 3 study.
    • 11 Oct 2018 Status changed from recruiting to discontinued, according to an Immune Design media release.
    • 01 Aug 2018 According to an Immune Design media release, company plans to present long-term follow-up data from its CMB305 monotherapy trial in soft tissue sarcoma patients at the European Society for Medical Oncology (ESMO) 2018 Congress in October.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top